PTC Therapeutics
E561093
PTC Therapeutics is a biopharmaceutical company focused on developing small-molecule and RNA-based therapies for rare genetic disorders and other serious diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| PTC Therapeutics canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6004769 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: PTC Therapeutics Context triple: [risdiplam, developedBy, PTC Therapeutics]
-
A.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company best known for developing transformative therapies for cystic fibrosis and other serious diseases using a precision medicine approach.
-
B.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
C.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
D.
Idera, Inc.
Idera, Inc. is a software company best known for its database management, performance monitoring, and developer tools used by IT professionals and enterprises.
-
E.
Perrigo
Perrigo is a global healthcare company best known for manufacturing and distributing over-the-counter and generic prescription pharmaceuticals, consumer healthcare products, and nutritional items.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: PTC Therapeutics Target entity description: PTC Therapeutics is a biopharmaceutical company focused on developing small-molecule and RNA-based therapies for rare genetic disorders and other serious diseases.
-
A.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company best known for developing transformative therapies for cystic fibrosis and other serious diseases using a precision medicine approach.
-
B.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
C.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
D.
Idera, Inc.
Idera, Inc. is a software company best known for its database management, performance monitoring, and developer tools used by IT professionals and enterprises.
-
E.
Perrigo
Perrigo is a global healthcare company best known for manufacturing and distributing over-the-counter and generic prescription pharmaceuticals, consumer healthcare products, and nutritional items.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| collaboratesWith |
Roche
NERFINISHED
ⓘ
SMA Foundation NERFINISHED ⓘ |
| conducts | clinical trials ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| develops |
RNA-based therapies
ⓘ
small-molecule therapies ⓘ |
| engagesIn |
commercialization of medicines
ⓘ
drug discovery ⓘ preclinical development ⓘ |
| focusesOn |
rare genetic disorders
ⓘ
serious diseases ⓘ |
| foundedBy | Stuart W. Peltz NERFINISHED ⓘ |
| hasBusinessModel | research and development of proprietary therapeutics ⓘ |
| hasDrug |
Emflaza
NERFINISHED
ⓘ
Evrysdi NERFINISHED ⓘ Translarna NERFINISHED ⓘ Upstaza NERFINISHED ⓘ |
| hasDrugIndication |
Duchenne muscular dystrophy
NERFINISHED
ⓘ
aromatic L-amino acid decarboxylase deficiency ⓘ spinal muscular atrophy ⓘ |
| hasEmployeeType |
clinical development professionals
ⓘ
regulatory affairs professionals ⓘ research scientists ⓘ |
| hasKeyPerson |
Matthew B. Klein
NERFINISHED
ⓘ
Stuart W. Peltz NERFINISHED ⓘ |
| hasMarket | global rare disease market ⓘ |
| hasTherapeuticArea |
central nervous system disorders
ⓘ
genetic diseases ⓘ metabolic disorders ⓘ neuromuscular disorders ⓘ oncology ⓘ |
| headquartersLocation | South Plainfield, New Jersey, United States NERFINISHED ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| regulatoryRegion |
European Union
NERFINISHED
ⓘ
Latin America NERFINISHED ⓘ United States NERFINISHED ⓘ |
| researchFocus | nonsense mutation readthrough ⓘ |
| targetsPatientPopulation |
patients with rare diseases
ⓘ
pediatric patients ⓘ |
| tradedAs | NASDAQ:PTCT NERFINISHED ⓘ |
| usesModality |
RNA splicing modulation
ⓘ
gene therapy ⓘ small molecules ⓘ |
| website | https://www.ptcbio.com ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: PTC Therapeutics Description of subject: PTC Therapeutics is a biopharmaceutical company focused on developing small-molecule and RNA-based therapies for rare genetic disorders and other serious diseases.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.